Consort Medical has announced record revenue and profits for the year ending April 30, 2012, including a 12% increase in revenue for its Bespak division, which manufactures metered dose inhaler valves and actuators as well as dry powder inhalers. Bespak’s operating profit also grew by 17%.
According to Consort, the growth in Bespak revenue came about in part due to three new development contracts, the launch of a device using the company’s dose counter in the US, and a 12% increase in MDI valve sales volumes. The company previously announced that one of the development contracts concerns a nicotine delivery device.
Consort Medical CEO Jon Glenn said, “We are delighted that Consort Medical has delivered record revenues and profits in this uncertain global economic environment. During the year, we have launched two major new products, Bespak’s Integrated Dose Counter and the King Vision laryngoscope, as well as expanding our growth pipeline with three new development contracts. Our core business continues to perform well and our new diversified range of opportunities positions us well for sustained future growth.”
Read the Consort press release.
